Dewpoint Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Dewpoint Therapeutics's estimated annual revenue is currently $34.7M per year.
- Dewpoint Therapeutics's estimated revenue per employee is $193,750
- Dewpoint Therapeutics's total funding is $287M.
Employee Data
- Dewpoint Therapeutics has 179 Employees.
- Dewpoint Therapeutics grew their employee count by -2% last year.
Dewpoint Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $5.2M | 67 | -45% | $107.3M | N/A |
#2 | $0.3M | 2 | 0% | N/A | N/A |
#3 | $5.1M | 33 | 6% | N/A | N/A |
#4 | $11.9M | 77 | -37% | $312.8M | N/A |
#5 | $0.9M | 6 | 0% | N/A | N/A |
#6 | $235M | 300 | -5% | $340.9M | N/A |
#7 | $45.9M | 237 | -7% | $7.6M | N/A |
#8 | $3.9M | 50 | 35% | N/A | N/A |
#9 | $7M | 45 | 73% | N/A | N/A |
#10 | $5.4M | 35 | 3% | N/A | N/A |
What Is Dewpoint Therapeutics?
Dewpoint Therapeutics is the first company founded to apply the emerging discipline of biomolecular condensates to drug discovery. Dewpoint believes that a vast range of conditions have pathways that are regulated by condensates or arise from the dysfunction of condensates ￃﾢ￢ﾂﾬ￢ﾀﾝ including cancer, neurodegeneration, and metabolic disease. Dewpoint scientists are working in Boston, MA, and Dresden, Germany, to translate condensate biology into treatments for the toughest diseases.
keywords:N/A
$287M
Total Funding
179
Number of Employees
$34.7M
Revenue (est)
-2%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Dewpoint Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | SVP | Reveal Email/Phone |
2 | VP, Head R&D Strategic Planning and Operations | Reveal Email/Phone |
3 | Sr. Principal Scientist | Reveal Email/Phone |
4 | Associate Director, R&D Strategic Planning & Operations Lead | Reveal Email/Phone |
5 | SVP | Head Digital and Technology Platforms | Executive Leadership Team | Reveal Email/Phone |
6 | VP, Research and Development | Reveal Email/Phone |
7 | VP, Head Neurological & Rare Diseases | Reveal Email/Phone |
8 | Director, R&D Program, Alliance & Operations Management | Reveal Email/Phone |
9 | Head Discovery Platform | Reveal Email/Phone |
10 | Executive Assistant to the CSO | Reveal Email/Phone |
Dewpoint Therapeutics News
... and has successfully attracted investors, including raising $11 million for Trek Therapeutics and $77 million for Dewpoint Therapeutics.
BOSTON, Jan. 6, 2021 /PRNewswire/ -- Dewpoint Therapeutics, the biomolecular condensates company, today announced a new research collaboration with Pfizer (NYSE: PFE) for the development of potential therapeutics for the treatment of myotonic dystrophy type 1, DM1, a rare genetic disorder and ...
BOSTON, Sept. 29, 2020 /PRNewswire/ -- Dewpoint Therapeutics, the biomolecular condensates company, today announced it has raised $77 million in a Series B financing. The round was led by ARCH Venture Partners, with participation from new investors Maverick Ventures and Bellco Capital, and exi ...
Dewpoint Therapeutics was founded because “the pharma industry has kind of been fighting with one arm behind its back,” the company's CEO Amir Nashat said, citing his colleague Mark Murcko. Sponsored by Agilent Technologies How would you like to win free bench space at Lab Central for one scie ...
Other Companies in Boston
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $28.6M | 179 | 33% | N/A |
#2 | $63.6M | 179 | N/A | N/A |
#3 | $35.6M | 180 | 8% | N/A |
#4 | $49.5M | 180 | 20% | N/A |
#5 | $41.6M | 180 | -29% | N/A |